GSK, Zofran Users To Pick 16 Potential MDL Bellwether Cases

Law360, Boston (May 17, 2018, 3:33 PM EDT) -- GlaxoSmithKline and the families who claim its anti-nausea medication Zofran caused various birth defects will each select eight cases to probe and possibly bring to trial in the multidistrict litigation’s final discovery phase, a Massachusetts federal judge ruled Thursday.

U.S. District Judge F. Dennis Saylor IV said the time is nearing for GSK and the families to begin picking appropriate cases to bring to trial and selected a number closer to what the families had asked for when the two sides squabbled over the scope of discovery in a Boston courtroom last month. More than 400 cases have been consolidated in...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!